
Request appointment
22 S. Greene StBaltimore, MD 21201
Fax+1 410-328-1975
Overview of Dr. Badros
Dr. Ashraf Badros is an oncologist in Baltimore, MD and is affiliated with University of Maryland Medical Center. He received his medical degree from Ain Shams University Faculty of Medicine and has been in practice 41 years. Dr. Badros accepts several types of health insurance, listed below. He is one of 113 doctors at University of Maryland Medical Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
MedStart Georgetown University HospitalFellowship, Medical Oncology, 1994 - 1996
MedStar Health Georgetown University/Harbor HospitalResidency, Internal Medicine, 1990 - 1993
Ain Shams University Faculty of MedicineClass of 1985
Certifications & Licensure
MD State Medical License 1991 - 2028
AR State Medical License 1998 - 2002
DC State Medical License 1994 - 1998
NY State Medical License 1993 - 1994
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
- Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Publications & Presentations
PubMed
- Predictors of Rehabilitation Utilization After CAR T-Cell Therapy.Hanan Alharthy, Abdulaziz Abu-Haimed, Renu E Thomas, Graeme A Fenton, Justin W Kehm
Transplantation and Cellular Therapy. 2026-11-01 - Changes in C-Reactive Protein Forecast Infection Risk Following Treatment with Chimeric Antigen Receptor T Cells.Poonam Mathur, Hegang Chen, David J Riedel, Elizabeth Holland, Danica Palacio
Cancers. 2026-09-09 - Beyond the typical immune effector cell-associated neurotoxicity syndrome: Characterizing non-immune effector cell-associated neurotoxicity syndrome neurological compl...Melissa A Nicholas, Abdulaziz Abu-Haimed, Faisal Abushullaih, Emily N Davidson, Graeme A Fenton
Neuro-Oncology Advances. 2026-08-05
Abstracts/Posters
- Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain BarrierAshraf Z. Badros, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...Ashraf Z. Badros, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)Ashraf Z. Badros, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis (BKV-HC) Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Novel Approaches to Newly Diagnosed Plasma Cell Dyscrasias2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
5 Cancer Services with Big Patient Results, Per LeadersJuly 14th, 2025
DARZALEX® (Daratumumab)-Based Maintenance Regimens Show Clinically Meaningful Deep and Durable Responses in Transplant-Eligible Patients with Newly Diagnosed Multiple MyelomaSeptember 27th, 2024
International Myeloma Foundation Launches Baltimore-Area Campaign to Raise Disease Awareness and Improve Outcomes in the African-American CommunitySeptember 9th, 2021
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CareFirst BCBS Maryland POS
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open AccessCIGNA PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: